Psychedelic Therapy and Depression: What the Research Shows

Psychedelic-assisted therapy is one of the most closely watched areas of depression research. Clinical trials pairing substances like psilocybin with structured psychotherapy have reported encouraging results, particularly for treatment-resistant depression, and regulators have judged the evidence incomplete: Health Canada has not authorized any psychedelic as a treatment for depression, and larger trials are still underway. This article covers where the research stands, how trials work, and what the risks are.

Can you take psychedelics for depression?

Not legally in Canada, outside of narrow circumstances. Psilocybin, MDMA, and most other psychedelics are controlled substances, and Health Canada has not authorized any of them as a treatment for depression or any other condition. The only lawful way to receive them is through a federally authorized clinical trial or other tightly controlled, practitioner-initiated pathways.

Within those research settings, psychedelics are almost never studied on their own. Trials pair the drug experience with structured psychotherapy before, during, and after the dosing session, and researchers believe the therapy component is central to any benefit.

What is psychedelic therapy for depression?

In depression trials, psychedelic-assisted therapy typically follows a four-step framework:

• Step 1: Screening and education. Researchers assess whether a participant is eligible, review their medical and psychiatric history, and explain the potential benefits and risks of taking part. Screening matters especially for depression, since people with certain conditions or on certain medications are excluded from trials.

• Step 2: Preparation. The participant attends one or more sessions with the study's therapists to prepare for the dosing session, set expectations, and build trust with the team who will be present.

• Step: 3: The dosing session. The participant receives the drug in a controlled setting, with trained facilitators present for the entire session, which can last several hours.

• Step 4: Integration. In follow-up sessions, the participant works with a therapist to process and contextualize the experience. The experience can be confusing or distressing, and researchers consider this stage essential to any therapeutic effect.

Protocols vary between studies, and researchers are still working out which elements matter most.

Psychedelics carry real risks for people with depression, including difficult experiences during and after use. Anyone seeking help for depression can work with a licensed therapist using established, legal approaches with decades of evidence behind them.

How does psychedelic therapy work for depression?

Researchers are still working this out. In clinical trials, the integration stage is where participants work to draw insights from the experience, and researchers believe this stage is central to any therapeutic effect. The physical mechanisms are less understood, and to date there is no conclusive model explaining how psychedelics affect depression at the level of the brain.

The research is early but active. A systematic review and meta-analysis of 14 studies found short- and long-term symptom improvements associated with psilocybin, LSD, and ayahuasca paired with therapy, and a review of long-term effects looks at what is known about lasting changes from psychedelic use, an area where evidence remains thin. The usual caveats apply across this literature: small samples, difficulty blinding participants, and short follow-up periods, which is why no regulator has approved a psychedelic as a depression treatment.

What substances are being studied in psychedelic therapy for depression?

Researchers have studied several substances in combination with psychotherapy for depression, some far more thoroughly than others.

Psilocybin

Psilocybin is the active compound in "magic" mushrooms, and it is the most studied psychedelic for depression. Trials use synthetic, pharmaceutical-grade psilocybin in measured doses. Systematic reviews and meta-analyses report reductions in depressive symptoms among trial participants, including in reviews focused on major depressive disorder, while consistently noting the same limitations: small samples, blinding problems, and short follow-up. Larger trials are underway, and Health Canada has not approved psilocybin for any condition.

Ketamine

Ketamine is different from the other substances here: it is an approved anaesthetic in Canada, and physicians can legally prescribe it off-label. Research on ketamine and depression is comparatively advanced. A randomized clinical trial found rapid reductions in suicidal thoughts compared with an active control, and a large trial in the New England Journal of Medicine found ketamine performed comparably to electroconvulsive therapy for treatment-resistant depression. The durability of ketamine's effects remains an open question, and a ketamine-derived medication has been approved in Canada for treatment-resistant depression, available only through a physician. Off-label ketamine use is a decision made by a physician with their patient.

MDMA

MDMA (3,4-methylenedioxymethamphetamine) is a synthetic psychoactive drug first developed in the 1920s, and from the 1970s some therapists used it experimentally alongside psychotherapy. Its chemical structure resembles both methamphetamine and mescaline, and it acts on serotonin, dopamine, and norepinephrine systems. Most MDMA research has focused on PTSD rather than depression, and evidence for depression specifically is thin: a small number of reviews report short-term mood effects in trial participants, and no trial has established MDMA as a depression treatment.

LSD

Lysergic acid diethylamide (LSD) was first synthesized in 1938 by Albert Hofmann and was widely studied in the 1950s and 1960s before research largely stopped. It is a serotonin receptor agonist, and its exact mechanisms are not well understood. Modern evidence for LSD and depression is limited: systematic reviews of classical psychedelics draw mostly on older or small studies, and some modern research examines LSD's acute effects on emotional processing rather than depression outcomes.

Microdosing

"Microdosing" refers to taking small, sub-hallucinogenic amounts of psychedelics on an ongoing basis. The evidence for depression is weak. Survey studies report that people who microdose describe lower levels of anxiety and depression than non-microdosers, but these are self-reports from people who chose to microdose, not controlled trials. Reviews of the field note that placebo-controlled studies have generally struggled to distinguish microdosing's effects from placebo.

What are the effects of psychedelic therapy for depression?

Effects vary widely depending on the substance, the dosage, the therapeutic framework, and the severity of symptoms. The time course varies too: ketamine studies have reported rapid reductions in some symptoms, including suicidal thinking, though these effects often fade within days or weeks and researchers are still studying how to sustain them. For microdosing, controlled studies have generally failed to show a benefit for depression at all.

Psychedelic experiences are also highly subjective. One trial participant may describe a profound mental or spiritual epiphany, while another, at the same dose, may find the experience frightening or destabilizing. For people with depression, difficult experiences carry particular weight, which is why trial protocols keep trained facilitators present throughout the dosing session and treat integration as essential. In follow-up sessions, participants work with therapists to make sense of what happened, whether the experience was positive or difficult.

Psychedelics and antidepressants

Few studies have examined the risks of combining psychedelics with antidepressants, and the risks differ by substance. In clinical trials, participants taking SSRIs are typically tapered off under medical supervision before receiving the study drug, for two reasons:

• Serotonin syndrome. Certain substances, particularly MDMA and ayahuasca (which contains MAO inhibitors), can interact with SSRIs and cause serotonin syndrome, a serious and potentially fatal condition.
• Blunted effects. Some antidepressants appear to reduce the effects of psychedelics like psilocybin, which complicates research and means the interactions are not fully understood.

Psilocybin, LSD, and pure DMT act differently from MDMA and ayahuasca and are not typically associated with serotonin syndrome, though data on their interactions with antidepressants remains limited.

Before you stop taking any medication you've been prescribed, whether all at once or by tapering, talk to your prescribing doctor. Quitting antidepressants may cause antidepressant discontinuation syndrome, which has wide-ranging negative effects. It can also lead to a return of symptoms, including suicidal ideation.

Key takeaways:

• Psychedelics are controlled substances in Canada, and none have been authorized by Health Canada as a treatment for depression or any other condition. The only lawful access is through clinical trials and other narrow, federally controlled pathways.
• Psilocybin is the most studied psychedelic for depression, and regulators consider the evidence incomplete: trials are promising, small, and hard to blind, and larger studies are underway.
• Ketamine is the exception in legal status: it is an approved anaesthetic that physicians can prescribe off-label, a decision made between a doctor and their patient.
• Trials pair the drug with structured preparation and integration therapy, and researchers believe the therapy component is central to any benefit.
• Anyone seeking help for depression can work with a licensed therapist using established, legal approaches with decades of evidence behind them.